These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Pilot Clinical Evaluation of PoreSkin: A Human Acellular Dermal Matrix in Burn Scars.
    Author: Angspatt A, Termwattanaphakdee T, Muangma P, Bunaprasert T.
    Journal: J Med Assoc Thai; 2017 Apr; 100(4):441-6. PubMed ID: 29911847.
    Abstract:
    BACKGROUND: An extensive full-thickness wound need a graft, sometime very large. However, donor sites are often limited. Dermal substitutes are among the tissue-engineered products applied to clinical use. PoreSkin, a human acellular dermal matrix (hADM) manufactured by the Faculty of Medicine, Chulalongkorn University, is the first human dermal substitute developed in Thailand. OBJECTIVE: Assess the safety and ability in achieving durable and definitively cosmetic coverage using PoreSkin. MATERIAL AND METHOD: Eleven hypertrophic burn scars were enrolled in the present study. After scar excision, PoreSkin was placed followed by delayed split-thickness skin graft, three weeks later. The primary outcomes were the engraftment rate of the Poreskin and the skin graft. The secondary outcomes included complications and the final cosmetic appearance. RESULTS: The engraftment rate of PoreSkin was 97.7% at day 21. The engraftment rate of autologous sheet skin graft placed over PoreSkin was 91.8%. Regarding the quality of the scar, using the Vancouver scar scale, it shows a statistically significant improvement (p<0.05). No major complications or rejection were observed. CONCLUSION: The performance of PoreSkin as a human acellular dermal matrix (hADM) is comparable to other commercial dermal substitutes in term of engraftment rate, complications, and rejection.
    [Abstract] [Full Text] [Related] [New Search]